CD79A and inflammatory bowel disease: It was shown that mono-GO changed many pathways, such as Th1 and Th2 cell differentiation, IL-17 signaling pathway, cytokine-cytokine receptor interaction, ribosome, oxidative phosphorylation and inflammatory bowel disease (IBD), etc. However, the signal pathways changed by multi-GO were different from mono-GO, such as cysteine and methionine metabolism, asthma, synaptics vesicle cycle, and intestinal immune network for IgA production, etc.